MSA-2

129425-81-6

294.32

DMSO : 50 mg/mL (ultrasonic; warming; heat to 80C)

Immunology/Inflammation

MSA-2, a potent and orally available non-nucleotide STING agonist, has EC₅₀s of 8.3 and 24 uM for human STING isoforms WT and HAQ, respectively. MSA-2 shows antitumor activity and stimulates interferon-beta secretion in tumors, induces tumor regression with durable antitumor immunity, and synergizes with anti-PD-1 in syngeneic mouse tumor models^[1]. In Vivo: MSA-2 dosed via either PO or SC regimens achieved comparable exposure in both tumor and plasma. MSA-2 also exhibits dose-dependent antitumor activity when administered by IT, SC, or PO routes, and dosing regimens were identified that induced complete tumor regressions in 80 to 100% of treated animals^[1].
MSA-2 (PO: 60 mg/kg or SC: 50 mg/kg; single dose) that effectively inhibits tumor growth induced substantial elevations of IFN-beta, interleukin-6 (IL-6), and TNF-alpha in tumor^[1].